REMINDER: Our user survey closes on Friday, please submit your responses here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
BD, ur most welcome. Rep., sounds like a plan :)
Some great info on this thread chaps, we're clearly onto something decent here.
I think the recent press releases in relation to the SGS trial have spread good awareness about the drug and it's potential, but of course there was no mention of Vela in the articles. We as shareholders could just do with news of Vela's investment within the trial being publicised, which should really get the ball rolling here.
I'll take to Twitter later on to spread some awareness.
Tra1, thks for the links, they both look like sweet deals. The Bayer deal appears to be only for the China region so globally potentially multiples thereof & the C4XD deal again looks very encouraging in terms of value. Does seem that an upfront payment plus on-going royalties is the standard approach.
Bayer - an upfront payment of 300 million yuan ($43.3 million) and additional payments could reach up to 4.18 billion yuan if certain milestones are met.
C4XD - Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi
https://www.c4xdiscovery.com/news/press-releases/exclusive-worldwide-licensing-agreement-with-sanofi-c4xd-il17a.html
another similar drug has been approved recently:
https://finance.yahoo.com/news/vtv-therapeutics-vtvt-gets-breakthrough-130301989.html
P.s just added a bit to #spc as well
Also depends on whether we keep our interest or if JN sells part of or all of our interest for a cash sum.. very exciting times
just an example:
https://www.chinadaily.com.cn/a/202008/18/WS5f3b980fa310834817261177.html
also there was something like that with #C4X recently
I would assume, if commercialised, that it would have a widespread use as it deals with diabetes as well as Covid. Could it be used as diabetic pill on its own without the side line of being used on covid patients? if so, and shown to lower blood glucose levels in patients for up to 4 months then surely it would become a mass market drug and worth a few pennies?
not sure.... would it depend on where its sold( europe / Asia/ GLOBAL!!!
MriGoat, Yes that is right although some of those patients will still be in the trial period. At least 120 patients must have fully completed the trial by now and outcome known with the balance competing over the next 4 weeks or so.
Anyone got any estimates of what a successful phase II drug trial is worth? Or looking at it another way, what sort of return would one expect on a £2.35m investment?
BD, think the last update was 144 /150 patients or 96% from the last SGS update RNS?? So completely agree discussions must be taking place especially as 'we expect to agree a commercial deal with a partner immediately' .
From the rns on the 18th December where dave states if the drug is a success they will be able to agree a deal almost immediately, I'd say that there have been talks ongoing with, I presume AstraZeneca, throughout the trial, as to the ongoing progress of the trials. Just a matter of time now!
Should get an update once all patient's are recruited then we should see people start taking a position here, as someone pointed out we are the only listed company with an interest. Look what happened here with knb when we only had 150000 invested. Gla
Wouldn't surprise me if he is already in 'off the record' preliminary discussions. At least 80% of patients now completed trial (based on mid Mar update of 120 on boarded). He knows where this is going and so do the pharma companies looking to get a slice of the action.
Think missed the boat with RMM, been in my watch list for about a year. Been held in the low .30 for ages until now.
well, best time to take position now especially with the last update D Tapolczay already talking about commercialisation deal.
"The final study visit ('Last Patient Out' date) will be no more than 28 days after completion of enrolment"
Exciting times ahead!
Yep, could be at the 150 patients this week. Don't forget, need to allow a further 28 days for those final patients to undertake and complete the trial. So once we hit mid May, it is game on.
nah, it is ok, the ask/bid is the same i think someone is playing with spread bet/cfd
Jinxed it! LOL
strong today, could be the last week at these prices, trial was almost complete last week